乳腺癌患者有无面罩固定的PBS质子治疗剂量递送可重复性
该回顾性研究纳入2019年1月至2022年9月间接受质子笔束扫描(PBS)治疗的94例乳腺癌患者,比较有面罩固定(69例)与无面罩固定(25例)的剂量递送可重复性。结果显示两组计划与验证CT剂量参数平均差异分别小于2.2%和3.7%,无面罩组出现大剂量劣化(LDD)的比例更高,但两组中引起临床关注的剂量差异均可通过重新计划解决。
要点
- 有面罩固定患者计划与验证CT的CTV/OAR剂量参数平均差异小于2.2%,无面罩固定患者小于3.7%。
- 有面罩固定与无面罩固定患者至少一次CTV或OAR验证CT剂量LDD的比例分别为20.3%和72.0%。
- 两组中引起临床关注的剂量差异均通过重新计划得以解决。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Setup reproducibility of the tissue in the proton beam path is critical in maintaining the planned clinical target volume (CTV) dose coverage and sparing the organs at risk (OAR). In this study, we retrospectively evaluated radiation therapy dose reproducibility for proton pencil beam scanning (PBS) treatment of breast cancer patients with and without mask immobilization. METHODS: Ninety-four patients treated between January 2019 and September 2022 with at least one verification CT scan (V-CT) in treatment position were included for this study. All patients were set up with arms up using the Orfit AIO patient positioning system, with (69 patients) or without (25 patients) mask immobilization in chin, neck, shoulder, upper arm, and chest areas. Two to three enface or near enface single field uniform dose PBS beams were optimized using a commercial treatment planning system. Prescription doses were 25 to 60 GyRBE in 5 to 45 fractions. Treatment plan doses re-calculated on V-CTs were compared to the corresponding planned doses. Cumulative doses were also calculated for patients with at least 3 V-CTs by deform and weighted sum doses from V-CTs to corresponding P-CTs. CTV D95%, ipsilateral-lung V40%, esophagus D0.01cc, and heart mean dose were evaluated and reported as percentages of prescription doses. Differences were large dose deteriorations (LDD) if: (1) CTV (V-CT/cumulative D95%) - (Planned D95%) < - 5%; or (2) Ipsilateral-lung (V-CT/cumulative V40%) - (Planned V40%) > 5%; or (3) Esophagus (V-CT/cumulative D0.01cc) - (Planned D0.01cc) > 10%; or (4) Heart (V-CT/cumulative mean) - (Planned mean) > 1.5%. RESULTS: On average, V-CT/cumulative and planned CTV/OAR dose parameter differences were less than 2.2%/1.7% and 3.4%/3.7% for masked and maskless patients, respectively. The percentages of patients with at least one CTV or OAR V-CT/cumulative dose LDD were 20.3%/25.0% and 72.0%/54.0% for masked and maskless patients, respectively. CONCLUSIONS: On average, masked/maskless setups achieved delivered and planned CTV/OAR dose parameters agreed within 2.2%/3.7% for PBS treatment of breast cancer patients in this study. Maskless patients had higher rate of CTV/OAR LDDs compared to masked patients. Dosimetric differences large enough to raise clinical concerns in either group were able to be addressed with replannings.
引用
- Kang Y, Bues M, Halyard MY, et al. Dose delivery reproducibility for PBS proton treatment of breast cancer patients with and without mask immobilization. Radiat Oncol. 2023. PMID: 37736727. doi:10.1186/s13014-023-02323-3
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。